Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
NCT07362017
This study is recruiting at 10 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Moderate-to-severe Chronic Plaque Psoriasis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Vanda Pharmaceuticals
- Last updated on ClinicalTrials.gov
- September 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Vanda Investigational Site · Glendale, AZ
California · 1
- Vanda Investigational Site · Fremont, CA
Florida · 1
- Vanda Investigational Site · Miami, FL
Indiana · 1
- Vanda Investigational Site · Indianapolis, IN
New Hampshire · 1
- Vanda Investigational Site · Portsmouth, NH
New York · 1
- Vanda Investigational Site · Rochester, NY
North Carolina · 1
- Vanda Investigational Site · Wilmington, NC
Texas · 2
- Vanda Investigational Site · San Antonio, TX
- Vanda Investigational Site · Webster, TX
Washington · 1
- Vanda Investigational Site · Spokane, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.